Moderna said on Wednesday the U.S. drug regulator will review its modified flu vaccine application, a week after rejecting ...

By Mariam Sunny and Michael Erman Feb 18 (Reuters) - Moderna said on Wednesday the U.S. Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday, ...

Moderna announced that the FDA agreed to review its application for a mRNA-based flu vaccine after it agreed to further study in older adults.

The disagreement between Moderna and the FDA has reached a resolution just eight days after the biotech received a Refusal-to-File letter in response to its application for mRNA-1010. Moderna will now ...

The FDA has accepted Moderna's revised ⁠approach, seeking full approval ⁠for the shot ‌for adults aged between 50 and 64, and accelerated approval for those aged 65 and above, the company said, adding ...

At any point prior to the deadlines, admission to certain academic programs may be closed. It is crucial that exchange student applications are received by the application deadline. ADMISSION & ...

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA ...

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

Moderna said the U.S. Food and Drug Administration has agreed to review its influenza vaccine, reversing an earlier decision to reject the application.